Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug targets brain tumors in short Pre-Surgery study

NCT ID NCT06636162

First seen Mar 01, 2026 · Last updated May 25, 2026 · Updated 12 times

Summary

This study tests an oral drug called DSP-0390 in 20 people with IDH-mutant gliomas who are scheduled for brain tumor removal. Participants take the drug for about two weeks before surgery, and researchers measure how much drug reaches the tumor and blood. The goal is to see if the drug can build up in the tumor and kill cancer cells by disrupting cholesterol metabolism. This is an early-phase trial focused on learning how the drug works in the body, not on curing the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOMA, MALIGNANT are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Washington University School of Medicine

    RECRUITING

    St Louis, Missouri, 63110, United States

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

Conditions

Explore the condition pages connected to this study.